Orphan drug reimbursement should consider more than cost, says Eurordis
This article was originally published in SRA
The European rare disease association Eurordis has called on drug reimbursement authorities to bear in mind that while orphan medicines may be expensive, there are relatively few of them and they will be taken by very small numbers of patients1.
You may also be interested in...
The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.